This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Carnevale: Is AmSurg a Perfect Obamacare Growth Stock?

Most importantly, freestanding surgical centers like AmSurg operates can provide the same surgeries at approximately half the cost if done in a hospital outpatient department.

AmSurg claims an uncatchable market position in gastrointestinal (GI) procedures. Currently, it performs over 1.5 million procedures and over one million of those are in the GI area. The company claims to perform between 10% and 15% of all colon cancer screens in the United States. Nevertheless, the company is evolving into other high-growth areas such as multi-specialty.

Currently, AmSurg operates in 35 states. Moreover, the company is already the market leader in freestanding ASC (Ambulatory Surgical Centers) with approximately a 10% market share, and in ophthalmology they command approximately a 5% market share. Therefore, although it is one of the largest players in the market, there remains a lot of room for future growth.

Moreover, Holden reported the vast majority of surgery centers are still independent today. Corporate owner managers like AmSurg have less than 30% market share. Therefore, he believes "corporatizing" and consolidation provide growth potential at a rapid rate.

The demographic opportunity of our aging population is no secret. However, health-care reform presents many challenges for delivering the surging demand for health-care profitably. AmSurg offers a low-cost surgical alternative.

At the time of publication the author had no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMSG $78.59 -1.80%
AAPL $112.91 -0.34%
FB $89.52 -1.60%
GOOG $619.27 -1.80%
TSLA $249.00 0.21%

Markets

Chart of I:DJI
DOW 16,562.60 -80.41 -0.48%
S&P 500 1,974.38 -14.49 -0.73%
NASDAQ 4,778.4870 -49.8380 -1.03%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs